- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Oncotype DX DCIS Can Predict Recurrence in Women With DCIS
Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery for DCIS.
A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, according to data from a large, population-based study presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9—13. The test could provide important individualized information on the risk of recurrence after treatment by breast-conserving surgery, which can help better inform physicians and patients on their future risks and the need for additional treatment.
“We found that the DCIS Score was a good predictor of whether a patient with DCIS who was treated with breast-conserving surgery alone would experience recurrence of DCIS or invasive breast cancer in the same breast,” said Eileen Rakovitch, MD, an associate professor and radiation oncologist at Sunnybrook Health Sciences Centre and scientist at Sunnybrook Research Institute in Toronto, Ontario. “These data confirm the results of a study reported last year but in a more diverse population.
Complete article on AACR's website: http://bit.ly/1worX4m
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
